Successful Hemophilia B Gene Therapy In Dogs May Justify Human Experiments

January 04, 1999

CHAPEL HILL - Using gene therapy on experimental animals, researchers at the University of North Carolina at Chapel Hill and elsewhere have partially corrected the protein deficiency responsible for hemophilia B. The inherited illness, also known as Christmas disease, causes victims to bleed spontaneously, live severely restricted lives and often die prematurely.

Tests have shown that a unique strain of North Carolina hemophiliac dogs injected with corrected genes produced the blood clotting protein known as factor IX and are continuing to produce it steadily more than a year and a half after treatment, scientists say. Not making the clotting factor is what causes people and animals with the condition to bleed.

"The correction is modest, about 1 percent, but we believe that's enough to justify consideration of clinical trials in humans," said Dr. Timothy C. Nichols, associate professor of medicine and pathology at the UNC-CH School of Medicine. "This level of correction in humans could be enough to improve certain people with severe hemophilia, who bleed spontaneously, to the point where they would only bleed when injured. That would be a major improvement."

Two reports on the research appear in the Jan. 5 issue of Nature Medicine. Besides UNC-CH, other institutions involved include the universities of Pennsylvania and Washington at Seattle, Stanford University and biotechnology companies Avigen Inc. and Cell Genesys Inc. of Alameda and Foster City, Calif., respectively.

The dogs, which inherit hemophilia naturally just as humans do and have been bred for a half century at UNC-CH's Frances Owen Blood Research Laboratory, showed a dose response, Nichols said. That is, the more corrected gene they received, the more strongly their bodies responded. They tolerated the treatment and replacement therapy well.

"This dose response should identify the appropriate initial dose for use in humans," he said.

One report describes experiments in which corrected genes were injected into the dogs' muscles. The other involved injections into blood vessels leading to the liver, where factor IX is made normally.

"We and Dr. Katherine High of Penn reasoned that if you could just give patients a shot into muscle, gene therapy could work with little or no sedation, and it would be easier to get a clinical trial going and easier on patients." Nichols said. "We think the new work tends to confirm that."

Both studies employed a flu-like virus that had been rendered harmless as a vector to carry the corrected genes into muscle or liver cells where they could begin producing factor IX, he said.

Hemophilia B affects up to about 5,000 people in the United States and possibly 10 times that many worldwide, Nichols said. Currently, sales of an artificially produced factor IX that requires regular injections are between $500 million and $1 billion dollars annually, and that does not include treatment costs.

"From an expense point of view, the total cost of treating these patients is just extraordinary, especially when you think of it over a lifetime," he said. "The new work suggests that it's conceivable that appropriately selected patients could come into a clinic, get one or more shots that take less than an hour to administer and still be making clotting factor a year or two later. That would have a huge beneficial impact both for patients, who now have to come in several times a month, and their health-care costs."

Because of its hemophiliac dogs, the Frances Owen Blood Research Laboratory in UNC-CH's department of pathology and laboratory medicine, is a unique national and international medical research resource established by Dr. Kenneth M. Brinkhous, professor of pathology emeritus, and colleagues in the late 1940s. Previous forms of therapy for hemophilia, such as synthetic clotting factors, which worked in the dogs, also have worked in humans.

Besides Nichols and Brinkhous, UNC-CH authors of the reports include Drs. Hui-Feng Lin, Darrel W. Stafford, Marjorie S. Read and Dwight A. Bellinger and medical student Dan Elwell.

Hemophilia A, a different form of the illness caused by inadequate factor XIII production, is about five times as common as hemophilia B. Brinkhous and colleagues discovered and described factor XIII in the 1940s, developed the widely used partial thromboplastin time (PTT) test for detecting blood clotting disorders and developed a clotting factor concentrate, which was the first effective treatment for hemophilias.

The team plans to conduct comparable studies in UNC-CH hemophilia A dogs soon.
Note: Nichols can be reached at 804-794-4364 or 804-794-1619 until Dec. 30 and at 919-966-9339 (w) or 919-967-2495 (h) thereafter. His digital beeper is 216-2001, and email address is
Contact: David Williamson, 919-962-8596.

University of North Carolina at Chapel Hill

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to